Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04162210 · OUTCOME

Observed Plasma Concentrations of Belantamab Mafodotin- Antibody-drug Conjugate (ADC)

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Micrograms per milliliter (ug/mL)
Interval / dispersion
Standard Deviation
Time frame
Pre-dose on Day (D)1 of Cycles(C)1,2,3,4,6,9,12,18,24,30,36,42; End of Infusion (EOI) on D1 of C1,2,3,4&6; Start of infusion (SOI) + 2 hours(h) on D1,SOI + 24 h on D1; D4,D8-15,D22 of C1&C3; D1 of C2,3,4&6; C3D2; & End of Treatment(EOT) (~242 weeks)

What was measured

Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

Analysis population: Pharmacokinetic population included all participants in the safety analysis set who had at least 1 non-missing PK assessment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin217

Reported measurements

C1 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin206
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin0.36924.95969Not reportedNot reportedNot reported
C1 D1, EOI

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin205
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin47.333216.96867Not reportedNot reportedNot reported
C1 D1, SOI + 2 hours

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin106
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin41.574516.93490Not reportedNot reportedNot reported
C1 D2, SOI + 24 hours

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin201
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin27.60629.78065Not reportedNot reportedNot reported
C1 D4

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin111
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin14.09016.98060Not reportedNot reportedNot reported
C1 D8-15

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin112
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin5.35483.73879Not reportedNot reportedNot reported
C1 D22

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin23
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin1.79401.49303Not reportedNot reportedNot reported
C2 D1

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin3
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin34.866733.36770Not reportedNot reportedNot reported
C2 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin189
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin2.44595.19465Not reportedNot reportedNot reported
C2 D1, EOI

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin186
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin50.328119.73235Not reportedNot reportedNot reported
C3 D1

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin18
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin24.677023.95059Not reportedNot reportedNot reported
C3 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin148
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin3.25344.96069Not reportedNot reportedNot reported
C3 D1, EOI

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin147
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin48.051221.57493Not reportedNot reportedNot reported
C3 D1, SOI + 2 hours

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin75
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin42.468318.02709Not reportedNot reportedNot reported
C3 D2

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin2
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin35.25002.33345Not reportedNot reportedNot reported
C3 D2, SOI + 24 hours

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin125
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin32.875112.45517Not reportedNot reportedNot reported
C3 D4

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin69
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin21.589712.95046Not reportedNot reportedNot reported
C3 D8-15

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin69
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin8.99964.50886Not reportedNot reportedNot reported
C3 D22

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin14
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin3.28301.95202Not reportedNot reportedNot reported
C4 D1

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin2
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin36.330044.22246Not reportedNot reportedNot reported
C4 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin124
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin3.76205.53119Not reportedNot reportedNot reported
C4 D1, EOI

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin123
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin49.999817.69286Not reportedNot reportedNot reported
C6 D1

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin1
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin68.6000NANot reportedNot reportedStandard Deviation is not evaluable for a single participant.
C6 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin90
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin3.46712.09208Not reportedNot reportedNot reported
C6 D1, EOI

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin91
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin47.215322.86249Not reportedNot reportedNot reported
C9 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin63
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin3.95962.61261Not reportedNot reportedNot reported
C12 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin44
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin5.62986.30104Not reportedNot reportedNot reported
C18 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin25
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin4.79522.38870Not reportedNot reportedNot reported
C24 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin14
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin4.95182.60878Not reportedNot reportedNot reported
C30 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin6
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin4.51673.14142Not reportedNot reportedNot reported
C36 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin3
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin5.36874.47411Not reportedNot reportedNot reported
C42 D1, Pre-dose

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin1
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin1.2400NANot reportedNot reportedStandard Deviation is not evaluable for a single participant.
EOT (~242 weeks)

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin126
Values in Micrograms per milliliter (ug/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin2.96787.67752Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        4.95969
        value
        0.3692
    denoms
    1. counts
      1. group Id
        OG000
        value
        206
      units
      Participants
    title
    C1 D1, Pre-dose
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.96867
        value
        47.3332
    denoms
    1. counts
      1. group Id
        OG000
        value
        205
      units
      Participants
    title
    C1 D1, EOI
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.93490
        value
        41.5745
    denoms
    1. counts
      1. group Id
        OG000
        value
        106
      units
      Participants
    title
    C1 D1, SOI + 2 hours
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        9.78065
        value
        27.6062
    denoms
    1. counts
      1. group Id
        OG000
        value
        201
      units
      Participants
    title
    C1 D2, SOI + 24 hours
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        6.98060
        value
        14.0901
    denoms
    1. counts
      1. group Id
        OG000
        value
        111
      units
      Participants
    title
    C1 D4
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        3.73879
        value
        5.3548
    denoms
    1. counts
      1. group Id
        OG000
        value
        112
      units
      Participants
    title
    C1 D8-15
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.49303
        value
        1.7940
    denoms
    1. counts
      1. group Id
        OG000
        value
        23
      units
      Participants
    title
    C1 D22
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        33.36770
        value
        34.8667
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      units
      Participants
    title
    C2 D1
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        5.19465
        value
        2.4459
    denoms
    1. counts
      1. group Id
        OG000
        value
        189
      units
      Participants
    title
    C2 D1, Pre-dose
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        19.73235
        value
        50.3281
    denoms
    1. counts
      1. group Id
        OG000
        value
        186
      units
      Participants
    title
    C2 D1, EOI
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        23.95059
        value
        24.6770
    denoms
    1. counts
      1. group Id
        OG000
        value
        18
      units
      Participants
    title
    C3 D1
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        4.96069
        value
        3.2534
    denoms
    1. counts
      1. group Id
        OG000
        value
        148
      units
      Participants
    title
    C3 D1, Pre-dose
denoms
  1. counts
    1. group Id
      OG000
      value
      217
    units
    Participants
description
Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin
dispersion Type
Standard Deviation
groups
  1. description
    Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
    id
    OG000
    title
    Belantamab Mafodotin
param Type
MEAN
population Description
Pharmacokinetic population included all participants in the safety analysis set who had at least 1 non-missing PK assessment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points
reporting Status
POSTED
time Frame
Pre-dose on Day (D)1 of Cycles(C)1,2,3,4,6,9,12,18,24,30,36,42; End of Infusion (EOI) on D1 of C1,2,3,4&6; Start of infusion (SOI) + 2 hours(h) on D1,SOI + 24 h on D1; D4,D8-15,D22 of C1&C3; D1 of C2,3,4&6; C3D2; & End of Treatment(EOT) (~242 weeks)
title
Observed Plasma Concentrations of Belantamab Mafodotin- Antibody-drug Conjugate (ADC)
type
SECONDARY
unit Of Measure
Micrograms per milliliter (ug/mL)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice